1038-95-5, Name is Tri-p-tolylphosphine, molecular formula is C21H21P, belongs to chiral-phosphine-ligands compound, is a common compound. In a patnet, once mentioned the new application about 1038-95-5, Recommanded Product: 1038-95-5
Two new ternary platinum(II) complexes of general formula [Pt(DTC)LCl], where DTC = 4-(2-pyridyl)piperazine-1-carbodithioate (1 and 2) and L = tri(p-tolyl)phosphine (1) and tri(o-tolyl)phosphine (2), have been synthesized and characterized. Both complexes have shown phenanthriplatin and picoplatin type axial protection, albeit from both sides, offered by C?H moiety of the organophosphine (X-ray single crystal and DFT analysis). Furthermore, 2 has shown greater degree of axial shielding of platinum center than 1. In vitro anticancer activity against three cancer cell lines has revealed greater anticancer potency of 2 than 1. The activity against NF-kappaB (a cancer promoting protein) signified that death of the cancer cells may be due to hindering the activity of NF-kappaB and subsequent initiation of the apoptosis. High activity of 2 than 1 can be attributed to its greater lipophilicity and stronger axial protection (C?H?Pt = 2.752 A H?C?Pt 3.496 A ?H?Pt-P = 78.37 and ? C?Pt-P = 64.19), from both sides of the axial plane, that may hinder the diversion to off target biomolecules and thus may enhance cellular uptake. Based upon DNA binding and DNA denaturing studies with CT-DNA, a cooperative binding and non-intercalative (electrostatic/covalent) mode of interaction have been suggested.
Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Recommanded Product: 1038-95-5. In my other articles, you can also check out more blogs about 1038-95-5
Reference：
Phosphine ligand,
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate